AR071810A1 - Metodo de tratamiento de la disnea asociada con la insuficiencia cardiaca aguda. relaxina h2. uso. - Google Patents
Metodo de tratamiento de la disnea asociada con la insuficiencia cardiaca aguda. relaxina h2. uso.Info
- Publication number
- AR071810A1 AR071810A1 ARP090101762A ARP090101762A AR071810A1 AR 071810 A1 AR071810 A1 AR 071810A1 AR P090101762 A ARP090101762 A AR P090101762A AR P090101762 A ARP090101762 A AR P090101762A AR 071810 A1 AR071810 A1 AR 071810A1
- Authority
- AR
- Argentina
- Prior art keywords
- acute
- relaxin
- heart failure
- decompensated
- human subject
- Prior art date
Links
- 206010007556 Cardiac failure acute Diseases 0.000 title abstract 5
- 102000003743 Relaxin Human genes 0.000 title abstract 4
- 108090000103 Relaxin Proteins 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 208000000059 Dyspnea Diseases 0.000 abstract 2
- 206010013975 Dyspnoeas Diseases 0.000 abstract 2
- 230000001154 acute effect Effects 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 239000002220 antihypertensive agent Substances 0.000 abstract 1
- 229940127088 antihypertensive drug Drugs 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000035488 systolic blood pressure Effects 0.000 abstract 1
- 230000002861 ventricular Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2221—Relaxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/64—Relaxins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Metodos para reducir la descompensacion por intervencion aguda inclusive en los sujetos afectados con la insuficiencia cardiaca aguda descompensada. Metodos de tratamiento de la descompensacion card¡aca aguda mediante la administracion de una cantidad farmaceuticamente eficaz de relaxina. Reivindicacion 1: Una relaxina H2 con actividad farmaceutica caracterizada porque es para usar en un metodo para tratar la disnea en un sujeto humano. Reivindicacion 55: Uso de una relaxina H2 con actividad farmaceutica y una droga antihipertensiva caracterizado porque es en la fabricacion de un medicamento para tratar (a) la disnea en un sujeto humano; (b) la insuficiencia card¡aca aguda descompensada en un sujeto humano, donde el sujeto tiene insuficiencia cardiaca descompensada y una presion sangu¡nea sistolica de al menos 125 mm Hg; o (c) la insuficiencia cardiaca aguda descompensada en un sujeto humano, donde el sujeto tiene insuficiencia cardiaca aguda descompensada y una fraccion de eyeccion del ventr¡culo izquierdo de al menos 20%.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12788908P | 2008-05-16 | 2008-05-16 | |
US19054508P | 2008-08-28 | 2008-08-28 | |
US20124008P | 2008-12-08 | 2008-12-08 | |
US16433309P | 2009-03-27 | 2009-03-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR071810A1 true AR071810A1 (es) | 2010-07-14 |
Family
ID=40834101
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090101762A AR071810A1 (es) | 2008-05-16 | 2009-05-15 | Metodo de tratamiento de la disnea asociada con la insuficiencia cardiaca aguda. relaxina h2. uso. |
Country Status (30)
Country | Link |
---|---|
US (7) | US8053411B2 (es) |
EP (2) | EP2288373B1 (es) |
JP (4) | JP5651586B2 (es) |
CN (3) | CN103212063B (es) |
AR (1) | AR071810A1 (es) |
AU (1) | AU2009246114B2 (es) |
BR (1) | BRPI0913011A2 (es) |
CA (1) | CA2724540C (es) |
CR (1) | CR11749A (es) |
CY (1) | CY1116925T1 (es) |
DK (1) | DK2288373T3 (es) |
EA (2) | EA201500552A1 (es) |
ES (1) | ES2546287T3 (es) |
GB (2) | GB2462221B (es) |
HK (5) | HK1139051A1 (es) |
HR (1) | HRP20150845T1 (es) |
HU (1) | HUE025483T2 (es) |
IL (3) | IL208992A (es) |
MA (1) | MA32389B1 (es) |
MX (1) | MX2010012450A (es) |
MY (2) | MY159803A (es) |
NZ (3) | NZ701038A (es) |
PL (1) | PL2288373T3 (es) |
PT (1) | PT2288373E (es) |
SG (2) | SG191587A1 (es) |
SI (1) | SI2288373T1 (es) |
TW (1) | TWI386202B (es) |
UA (1) | UA99953C2 (es) |
WO (1) | WO2009140659A2 (es) |
ZA (1) | ZA201007449B (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG191587A1 (en) * | 2008-05-16 | 2013-07-31 | Corthera Inc | Treating dyspnea associated with acute heart failure with relaxin |
RU2512933C2 (ru) * | 2008-05-16 | 2014-04-10 | Кортера, Инк. | Способ лечения хронической сердечной недостаточности |
ES2541301T3 (es) | 2010-03-10 | 2015-07-17 | The University Of Melbourne | Modulación de acuaporinas con relaxina |
WO2012017071A1 (en) | 2010-08-06 | 2012-02-09 | Pronota N.V. | Perlecan as a biomarker for renal dysfunction |
US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
PL2605789T3 (pl) | 2010-08-17 | 2019-11-29 | Ambrx Inc | Zmodyfikowane polipeptydy relaksyny i ich zastosowania |
KR20140054009A (ko) * | 2011-07-01 | 2014-05-08 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 릴랙신 융합 폴리펩타이드 및 그의 용도 |
WO2013059879A1 (en) * | 2011-10-26 | 2013-05-02 | Howard Florey Institute Of Experimental Physiology And Medicine | Compositions and methods for the treatment of fibrosis and fibrotic diseases |
WO2013123094A2 (en) * | 2012-02-14 | 2013-08-22 | The Regents Of The University Of California | Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions |
US9452973B2 (en) | 2012-05-04 | 2016-09-27 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Modulators of the relaxin receptor 1 |
EA030354B1 (ru) * | 2012-10-26 | 2018-07-31 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Способ уменьшения диспноэ у пациента с острой сердечной недостаточностью |
MX367165B (es) | 2013-04-05 | 2019-08-07 | Scpharmaceuticals Inc | Formulaciones farmacéuticas para administración subcutánea de furosemida. |
US9707154B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
BR112016015281A8 (pt) * | 2014-02-03 | 2020-06-09 | Novartis Ag | uso de um filtro em linha intravenoso, e método para preparação de um conjunto de infusão |
EP2946788A1 (en) * | 2014-05-23 | 2015-11-25 | Immundiagnostik AG | Method and composition for treating heart failure with preserved ejection fraction |
AU2015273097A1 (en) * | 2014-06-13 | 2016-11-17 | Novartis Ag | Use of serelaxin to reduce GDF-15 |
WO2017100540A2 (en) | 2015-12-09 | 2017-06-15 | The California Institute For Biomedical Research | Relaxin immunoglobulin fusion proteins and methods of use |
WO2017139164A1 (en) | 2016-02-12 | 2017-08-17 | Cardiac Pacemakers, Inc. | Systems and methods for patient monitoring |
SG10201912034UA (en) | 2017-02-08 | 2020-02-27 | Bristol Myers Squibb Co | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
US11832970B2 (en) | 2017-07-26 | 2023-12-05 | Cardiac Pacemakers, Inc. | Worsening heart failure stratification |
CN107335051A (zh) * | 2017-08-18 | 2017-11-10 | 温州医科大学附属第医院 | 一种保护慢性心衰肾功能的药物组合物 |
CA3123718A1 (en) | 2019-01-04 | 2020-07-09 | Sq Innovation Ag | Pharmaceutical compositions of furosemide and uses thereof |
CN113747881B (zh) | 2019-01-31 | 2024-05-14 | Sc医药品有限公司 | 呋塞米的浓缩液体药物制剂及其给药方法 |
WO2024047130A1 (en) | 2022-08-31 | 2024-03-07 | Relaxera Pharmazeutische Gesellschaft mbH & Co. KG | Immunosuppressive medicament and method of treatment |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5023321A (en) | 1982-12-13 | 1991-06-11 | Howard Florey Institute Of Experimental Physiology & Medicine | Molecular cloning and characterization of a further gene sequence coding for human relaxin |
US5166191A (en) | 1991-08-19 | 1992-11-24 | Genentech, Inc. | Use of relaxin in cardiovascular therapy |
US5478807A (en) | 1991-08-19 | 1995-12-26 | Genentech, Inc. | Use of relaxin in the treatment of bradycardia |
EP0707650B1 (en) | 1993-06-21 | 2003-05-21 | Genentech, Inc. | Process for producing human relaxin |
DE69434777T2 (de) | 1993-07-27 | 2007-06-14 | Mario Bigazzi | Verwendung von Relaxin zur Herstellung von therapeutischer Mittel |
US5760069A (en) | 1995-02-08 | 1998-06-02 | Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 | Method of treatment for decreasing mortality resulting from congestive heart failure |
US5811395A (en) | 1995-06-07 | 1998-09-22 | Medical University Of South Carolina | Relaxin analogs and derivatives methods and uses thereof |
JP4568383B2 (ja) | 1995-08-15 | 2010-10-27 | コルセラ,インコーポレイティッド | 血管形成の促進方法 |
WO2001058468A1 (en) | 2000-02-09 | 2001-08-16 | Connetics Corporation | Use of relaxin to treat diseases related to vasoconstriction |
DE10155843A1 (de) * | 2000-11-16 | 2003-01-30 | Immundiagnostik Ag | Verfahren zur Prognose und Diagnose von Herzinsuffizienz |
US20050113286A1 (en) | 2002-03-18 | 2005-05-26 | Schreiner George F. | Methods for treating congestive heart failure |
US7878978B2 (en) | 2004-03-18 | 2011-02-01 | University Of Pittsburgh- Of The Commonwealth System Of Higher Education | Use of relaxin to increase arterial compliance |
US20070202080A1 (en) * | 2004-03-30 | 2007-08-30 | Industry-University Cooperation Foundation Yonsei | Gene Delivery System Containing Relaxin Gene And Pharmaceutical Composition Using Relaxin |
US20060264367A1 (en) | 2005-05-21 | 2006-11-23 | Howard Florey Institute | Prevention of fibrosis following cardiac injury |
TW200800206A (en) | 2005-07-11 | 2008-01-01 | Abbott Lab | Methods for determining how to treat congestive heart failure |
US8492329B2 (en) | 2007-07-12 | 2013-07-23 | Compugen Ltd. | Bioactive peptides and methods of using same |
RU2512933C2 (ru) | 2008-05-16 | 2014-04-10 | Кортера, Инк. | Способ лечения хронической сердечной недостаточности |
SG191587A1 (en) * | 2008-05-16 | 2013-07-31 | Corthera Inc | Treating dyspnea associated with acute heart failure with relaxin |
-
2009
- 2009-05-15 SG SG2013038260A patent/SG191587A1/en unknown
- 2009-05-15 WO PCT/US2009/044249 patent/WO2009140659A2/en active Application Filing
- 2009-05-15 CN CN201310127326.6A patent/CN103212063B/zh not_active Expired - Fee Related
- 2009-05-15 SI SI200931246T patent/SI2288373T1/sl unknown
- 2009-05-15 CN CN2009801177504A patent/CN102036679A/zh active Pending
- 2009-05-15 PT PT97477400T patent/PT2288373E/pt unknown
- 2009-05-15 US US12/467,214 patent/US8053411B2/en not_active Expired - Fee Related
- 2009-05-15 AR ARP090101762A patent/AR071810A1/es unknown
- 2009-05-15 EA EA201500552A patent/EA201500552A1/ru unknown
- 2009-05-15 MX MX2010012450A patent/MX2010012450A/es active IP Right Grant
- 2009-05-15 NZ NZ701038A patent/NZ701038A/en not_active IP Right Cessation
- 2009-05-15 ES ES09747740.0T patent/ES2546287T3/es active Active
- 2009-05-15 TW TW098116328A patent/TWI386202B/zh not_active IP Right Cessation
- 2009-05-15 UA UAA201012879A patent/UA99953C2/uk unknown
- 2009-05-15 EA EA201001771A patent/EA022948B1/ru not_active IP Right Cessation
- 2009-05-15 EP EP09747740.0A patent/EP2288373B1/en active Active
- 2009-05-15 NZ NZ589009A patent/NZ589009A/en not_active IP Right Cessation
- 2009-05-15 GB GB0918132A patent/GB2462221B/en not_active Expired - Fee Related
- 2009-05-15 MY MYPI2010005049A patent/MY159803A/en unknown
- 2009-05-15 US US12/992,356 patent/US8415301B2/en not_active Expired - Fee Related
- 2009-05-15 HU HUE09747740A patent/HUE025483T2/en unknown
- 2009-05-15 CN CN201610565105.0A patent/CN106177914A/zh active Pending
- 2009-05-15 JP JP2011509783A patent/JP5651586B2/ja not_active Expired - Fee Related
- 2009-05-15 SG SG10201609580YA patent/SG10201609580YA/en unknown
- 2009-05-15 GB GB0908432A patent/GB2459983B/en not_active Expired - Fee Related
- 2009-05-15 PL PL09747740T patent/PL2288373T3/pl unknown
- 2009-05-15 CA CA2724540A patent/CA2724540C/en not_active Expired - Fee Related
- 2009-05-15 DK DK09747740.0T patent/DK2288373T3/en active
- 2009-05-15 AU AU2009246114A patent/AU2009246114B2/en not_active Ceased
- 2009-05-15 EP EP14167842.5A patent/EP2829280A1/en not_active Withdrawn
- 2009-05-15 NZ NZ598709A patent/NZ598709A/xx not_active IP Right Cessation
- 2009-05-15 BR BRPI0913011A patent/BRPI0913011A2/pt not_active IP Right Cessation
-
2010
- 2010-05-18 HK HK10104896.5A patent/HK1139051A1/xx not_active IP Right Cessation
- 2010-07-28 HK HK10107238.5A patent/HK1140693A1/xx not_active IP Right Cessation
- 2010-10-19 ZA ZA2010/07449A patent/ZA201007449B/en unknown
- 2010-10-22 CR CR11749A patent/CR11749A/es unknown
- 2010-10-28 IL IL208992A patent/IL208992A/en not_active IP Right Cessation
- 2010-12-10 MA MA33418A patent/MA32389B1/fr unknown
-
2011
- 2011-05-30 HK HK15102533.3A patent/HK1202054A1/xx unknown
- 2011-05-30 HK HK11105324.3A patent/HK1151229A1/xx not_active IP Right Cessation
- 2011-09-23 US US13/242,012 patent/US8372809B2/en not_active Expired - Fee Related
-
2012
- 2012-09-12 JP JP2012200728A patent/JP5638044B2/ja not_active Expired - Fee Related
-
2013
- 2013-01-04 US US13/734,301 patent/US9066916B2/en not_active Expired - Fee Related
- 2013-03-05 US US13/784,963 patent/US9205132B2/en not_active Expired - Fee Related
- 2013-09-02 IL IL228244A patent/IL228244A/en not_active IP Right Cessation
- 2013-11-28 MY MYPI2013004312A patent/MY158327A/en unknown
-
2014
- 2014-01-23 HK HK14100736.3A patent/HK1187550A1/zh not_active IP Right Cessation
- 2014-08-14 JP JP2014165276A patent/JP5875646B2/ja not_active Expired - Fee Related
-
2015
- 2015-05-28 US US14/723,701 patent/US9579363B2/en not_active Expired - Fee Related
- 2015-08-10 HR HRP20150845TT patent/HRP20150845T1/hr unknown
- 2015-09-18 CY CY20151100824T patent/CY1116925T1/el unknown
- 2015-10-09 JP JP2015201153A patent/JP2016053040A/ja active Pending
-
2016
- 2016-08-18 IL IL247351A patent/IL247351A0/en unknown
-
2017
- 2017-01-23 US US15/412,447 patent/US20170151311A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR071810A1 (es) | Metodo de tratamiento de la disnea asociada con la insuficiencia cardiaca aguda. relaxina h2. uso. | |
AR083878A1 (es) | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento | |
NZ710157A (en) | Use of guanethidine for treating hypertension by local vascular delivery | |
AR047779A1 (es) | Composiciones y metodos para tratar diabetes | |
BR112013032265A2 (pt) | métodos de infusão de insulina subcutânea contínua com uma enzima de degradação do hialuronano | |
MX2023005455A (es) | Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil. | |
EA202090564A1 (ru) | Способы усиления и/или стабилизации сердечной функции у пациентов с болезнью фабри | |
AR103415A1 (es) | Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 | |
AR114392A1 (es) | Tratamiento de pacientes con enfermedad de fabry clásica | |
EA201792030A1 (ru) | Лечение пациентов с сахарным диабетом 2 типа | |
EA201691278A1 (ru) | Замещенные пиперидинил-тетрагидрохинолины | |
CL2021000444A1 (es) | Métodos para reducir el riesgo de diabetes en pacientes tratados por enfermedades relacionadas con el colesterol alto. | |
UA100883C2 (ru) | Применение дронедарона для получения лекарственного средства для лечения пациентов с аритмией и с повышенным уровнем креатинина в результате введения дронедарона | |
BR112019018861A2 (pt) | Uso de nitrito de sódio, método para manter os níveis fisiológicos de nitrito, prevenir enfarte do miocárdio, prevenir morte súbita cardíaca, prevenir acidente vascular cerebral, doenças cardiovasculares, pressão alta, solução aquosa | |
MX2021011711A (es) | Canagliflozina para el tratamiento de pacientes diabeticos con enfermedad renal cronica. | |
AR117861A1 (es) | Métodos de reducción de eventos cerebrovasculares en pacientes con enfermedad de fabry | |
AR061635A1 (es) | Tratamiento de insuficiencia cardiaca cronica leve en pacientes humanos | |
RU2006142622A (ru) | Способ лечения острого инфаркта миокарда | |
EA202192612A1 (ru) | Канаглифлозин для лечения больных диабетом пациентов с хроническим заболеванием почек | |
Lee | Phenylephrine/prednisolone acetate | |
CN109602811A (zh) | 一种治疗冠心病的药物 | |
RU2015134772A (ru) | Применение биматопроста для повышения выработки лептина | |
EA201591737A1 (ru) | Доставка sdf-1 для лечения ишемизированной ткани | |
CL2022000496A1 (es) | Métodos para el tratamiento de la enfermedad cln2 en sujetos pediátrico | |
Madias | Takotsubo Syndrome in a Patient With a Previously Repaired Tetralogy of Fallot |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |